- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05139095
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia: a Cohort, Open-label, Phase 2 Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational trophoblastic neoplasia (GTN).
Cohort A: Eligible patients will receive camrelizumab (200mg q2w iv) plus apatinib (250 mg qd po) plus chemotherapy. After normalization of serum β-human chorionic gonadotropin (β-hCG) levels, patients will receive 4 cycles of consolidation chemotherapy combined with camrelizumab plus apatinib and then 6 months of camrelizumab plus apatinib as maintenance treatment. Treatment will be continued until completion of treatment, disease progression, unacceptable toxicity, or withdrawal of consent.The primary endpoint is complete remission rate (the proportion of patients achieving complete remission). Secondary endpoints include objective response rate (the proportion of patients achieving complete remission and partial remission), progression-free survival (time from the treatment initiation to disease progression or death, whichever comes first), overall survival (time from the treatment initiation to the date of death or last follow-up), duration of response (time from the first evidence of response to disease progression or death, whichever comes first) and safety.
Cohort B: Eligible patients will receive camrelizumab (200mg q3w iv) plus apatinib (250 mg qd po) plus chemotherapy. Treatment will be continued until disease progression, unacceptable toxicity, or withdrawal of consent. Patients will receive 6 cycles of consolidation therapy if achieving a complete response. The primary endpoint is objective response rate. Secondary endpoints include progression-free survival, duration of response, overall survival and safety.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yang Xiang
- Phone Number: 010-69156068
- Email: XiangY@pumch.cn
Study Locations
-
-
-
Beijing, China
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- xiang yang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Woman aged 18-60 years;
- Previously untreated patients with ultra high-risk GTN(Cohort A) or high-risk chemo-refractory or relapsed GTN (Cohort B);
- No previous chemotherapy or radiotherapy for ultra high-risk GTN(Cohort A)and have previously received two or more lines of combination chemotherapies for high-risk chemo-refractory or relapsed GTN (Cohort B);
- Patients with ultra high-risk GTN (FIGO stages I-III: score ≥13 and stage IV) according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 staging and risk factor scoring system(Cohort A)and patients with a prognostic score ≥7 (Cohort B);
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Patients with abnormal serum hCG level (≥5 IU/L);
- Expected survival ≥ 4 months;
The function of vital organs meets the following requirements:
hemoglobin ≥90 g/L, absolute neutrophil count ≥1·5×109/L, platelets ≥100×109/L; creatinine ≤1·5 × upper limit of normal (ULN), urea nitrogen ≤2·5×ULN; total bilirubin ≤ULN, alanine aminotransferase and aspartate aminotransferase ≤2·5×ULN, albumin ≥25 g/L; thyroid stimulating hormone ≤ULN (if thyroid stimulating hormone is abnormal, normal T3 and T4 can also be acceptable).
- Female patients of childbearing age must exclude pregnancy and are willing to use a medically approved high-efficiency contraceptive (e.g., intrauterine device, contraceptive or condom) during the study period and within 6 months of the last study drug administration.
- The patient should be aware of the purpose of the study and the operations required by the study and volunteer to participate in the study before sign the informed consent form.
Exclusion Criteria:
- Previous treatment with immunotherapy drugs (including antibodies targeting PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, T-cell receptor, chimeric antigen receptor T-cell therapy, and other immunotherapy), anti-angiogenic small-molecule tyrosine kinase inhibitors (such as pazopanib, sorafenib, or regorafenib), or anti-angiogenic monoclonal antibodies (such as bevacizumab); live vaccines injected within 4 weeks before the first dose of study drug; other clinical trials of antitumour drugs within 4 weeks before the first dose of study drug;
- Other malignancies in the past 3 years;
- Immunosuppressive drugs used within 14 days prior to the first dose of camrelizumab; any active autoimmune disease or a history of autoimmune disease;
- Uncontrollable hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, despite with the optimal drug therapy);
- Grade II or higher myocardial ischemia, myocardial infarction or poorly controlled arrhythmia (females with QTc interval ≥470 ms); grade III to IV cardiac insufficiency according to New York Heart Association (NYHA) criteria, or cardiac color Doppler ultrasound evidence of left ventricular ejection fraction <50%; myocardial infarction, NYHA grade II or above heart failure, uncontrolled angina, uncontrolled severe ventricular arrhythmia, clinically significant pericardial disease, or electrocardiogram suggesting acute ischemia or abnormal active conduction system occurring within 6 months before enrolment;
- Abnormal coagulation (international normalised ratio >1·5×ULN or prothrombin time >ULN+4 seconds or activated partial thromboplastin time >1·5×ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy;
- Severe infections within 4 weeks prior to the first dose of study drug (e.g., need of intravenous infusion of antibiotics, antifungal or antiviral drugs), or unexplained fever (>38·5°C) during screening or the first dose of study drug;
- With a history of psychotropic drug abuse and are unable to withdraw the psychotropic drug, or have mental disorders;
- Major surgery performed within 4 weeks before the first dose of study drug, or open wounds or fractures;
- Obvious factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction, or sinus or perforation of empty organs within 6 months;
- Routine urine test indicating urinary protein ++ or more, or confirmed urinary protein ≥1·0 g within 24 hours;
- Human immunodeficiency virus infection or known acquired immunodeficiency syndrome, active hepatitis B (HBV DNA >500 IU/mL), hepatitis C (hepatitis C antibody positive, and HCV-RNA higher than the lower limit of the analysis method) or co-infection with hepatitis B and hepatitis C;
- Other reasons as judged by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Population: ultra high-risk gestational trophoblastic neoplasia
|
Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO [etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine] every 2 weeks.
For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO.
The observation period is 14 days.
Other Names:
|
Experimental: Cohort B
Population: high-risk chemo-refractory or relapsed gestational trophoblastic neoplasia
|
Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy.
The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO [etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine]; or EMA/EP [etoposide, methotrexate and actinomycin-D/etoposide, cisplatin]; or FAEV [floxuridine, actinomycin-D, etoposide, vincristine]).
The observation period is 21 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort A: Complete remission rate
Time Frame: up to one year
|
The proportion of patients achieving complete remission.
Complete remission is defined as normal serum β-hCG level measured for 3 consecutive weeks.
|
up to one year
|
Cohort B: Objective response rate
Time Frame: up to one year
|
The proportion of patients with complete or partial response according to serum β-hCG level.
Partial response is defined as a ≥50% decrease in β-hCG level from baseline after 2 cycles.
|
up to one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort A: Objective response rate
Time Frame: up to one year
|
The proportion of patients with complete or partial response according to serum β-hCG level.
|
up to one year
|
Cohort A: Progression-free survival
Time Frame: up to one year
|
The time from the treatment initiation to disease progression or death, whichever comes first.
Disease progression is defined as any increase in serum β-hCG level from baseline after 2 cycles of treatment or the presence of new metastatic lesions.
|
up to one year
|
Cohort A: Overall survival
Time Frame: up to one year
|
The time from the treatment initiation to the date of death or last follow-up.
|
up to one year
|
Cohort A: Duration of response
Time Frame: up to one year
|
The time from the first evidence of response to disease progression or death, whichever comes first.
|
up to one year
|
Cohort A: Frequency and severity of adverse events
Time Frame: up to one year
|
Determine frequency and severity of adverse events as assessed by NCI CTCAE (Version 5.0) which is used to evaluate the grade of adverse events, to observe any adverse event and serious adverse event that occurred in all patients during the clinical study period, including abnormal laboratory examination results, clinical manifestations and vital signs, to record their clinical manifestation characteristics, severity, occurrence time, duration, corresponding treatment and prognosis, and to determine their relationship with the study drug.
|
up to one year
|
Cohort B: Progression-free survival
Time Frame: up to one year
|
The time from the treatment initiation to disease progression or death, whichever comes first.
|
up to one year
|
Cohort B: Duration of response
Time Frame: up to one year
|
The time from the first evidence of response to disease progression or death, whichever comes first.
|
up to one year
|
Cohort B: Overall survival
Time Frame: up to one year
|
The time from the treatment initiation to the date of death or last follow-up.
|
up to one year
|
Cohort B: Frequency and severity of adverse events
Time Frame: up to one year
|
Determine frequency and severity of adverse events as assessed by NCI CTCAE (Version 5.0) .
|
up to one year
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms, Germ Cell and Embryonal
- Pregnancy Complications
- Pregnancy Complications, Neoplastic
- Trophoblastic Neoplasms
- Neoplasms
- Gestational Trophoblastic Disease
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- MA-GTN-II-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Trophoblastic Neoplasia
-
Ding MaShandong University; Huazhong University of Science and Technology; Zhejiang...UnknownGestational Trophoblastic Tumor | Gestational Trophoblastic Neoplasia | Gestational Trophoblastic Disease | Gestational Trophoblastic NeoplasmsChina
-
GOG FoundationNational Cancer Institute (NCI)CompletedHydatidiform Mole | Choriocarcinoma | FIGO Stage I Gestational Trophoblastic Tumor | FIGO Stage II Gestational Trophoblastic Tumor | FIGO Stage III Gestational Trophoblastic TumorUnited States, Korea, Republic of, Canada, Japan, United Kingdom
-
Hospices Civils de LyonCompletedGestational Trophoblastic Neoplasias (GTN)France
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedGestational Trophoblastic TumorUnited States, Norway
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompletedHydatidiform Mole | Good Prognosis Metastatic Gestational Trophoblastic Tumor | Non-Metastatic Gestational Trophoblastic Tumor | Uterine Corpus ChoriocarcinomaUnited States
-
xiang yangRecruitingGestational Trophoblastic Tumor | Gestational Trophoblastic Neoplasia | Choriocarcinoma | Stage I Gestational Trophoblastic Tumor | Stage II Gestational Trophoblastic Tumor | Stage III Gestational Trophoblastic Tumor | Invasive MoleChina
-
Brigham and Women's HospitalUniversidade Federal do Rio de Janeiro; Maternidade Escola da Universidade... and other collaboratorsRecruitingGestational Trophoblastic Neoplasia | Molar Pregnancy | Gestational Trophoblastic Tumor, Non-MetastaticBrazil
-
Women's Hospital School Of Medicine Zhejiang UniversityRecruitingStudy of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined ChemotherapyGestational Trophoblastic NeoplasiaChina
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Qilu Hospital of Shandong University; Huazhong University...RecruitingGestational Trophoblastic NeoplasiaChina
-
Hospices Civils de LyonMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...RecruitingGestational Trophoblastic Neoplasias (GTN)France
Clinical Trials on Camrelizumab plus apatinib CohortA
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking Union Medical College HospitalCompletedApatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | BiomarkerChina
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted TherapyChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingAdvanced Hepatocellular CarcinomaChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Henan Cancer HospitalRecruitingCamrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)Small Cell Lung CarcinomaChina
-
Shandong Provincial HospitalUnknown
-
Zhejiang UniversityHuashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaboratorsUnknownHepatocellular Carcinoma | Liver TransplantChina
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina